Background {#section5-1753466620926956}
==========

Interstitial lung disease (ILD) is a group of disorders that contains more than 200 entities characterized histopathologically by diffuse fibrotic and inflammatory abnormalities of the lung parenchyma.^[@bibr1-1753466620926956]^ Although the exact epidemiological data are not known, an earlier study indicated that the overall prevalence of ILD in New Mexico, United States, is 80.9 per 100,000 males and 67.2 per 100,000 females, corresponding with annual incidence rates of 31.5 per 100,000 males and 26.1 per 100,000 females.^[@bibr2-1753466620926956]^ The outcomes of various forms of ILD are quite different, with the highest 5-year survival rate of up to 91.6% observed in sarcoidosis compared with only 35.4% in idiopathic pulmonary fibrosis (IPF).^[@bibr3-1753466620926956]^

Acute respiratory failure (ARF) is one of the major complications of ILD and may result from acute exacerbation of ILD, infection, heart failure, or pulmonary venous thromboembolism.^[@bibr4-1753466620926956]^ Severe patients must be admitted to an intensive care unit (ICU). There are limited studies reporting the clinical features and outcomes of ILD patients developing ARF. A prediction model incorporating male sex, interstitial pulmonary fibrosis diagnosis, use of invasive mechanical ventilation (MV), extracorporeal life support, no ambulation within 24 h of ICU admission, higher body mass index, and higher severity scoring has been created for prediction of in-hospital mortality in patients with ILD admitted to an ICU.^[@bibr5-1753466620926956]^ The optimal strategy to manage ILD patients with ARF is not well established. However, among patients with idiopathic pulmonary fibrosis (IPF) and respiratory failure, MV is not recommended in the majority of patients.^[@bibr6-1753466620926956]^

The aim of the current study was to analyze the clinical features, mortality, and risk factors in ILD patients with ARF requiring MV.

Methods {#section6-1753466620926956}
=======

This is a retrospective observational study conducted in the medical ICU of a tertiary medical center in Taiwan. Patients admitted to the ICU with a past history or new diagnosis of ILD with ARF needing MV between January 2014 and December 2016 were included for analysis. Patient characteristics, including demographics, critical-illness factors and outcome data, were recorded and analyzed. The study was approved by the institutional review board of Taipei Veterans General Hospital (TPEVGH IRB No. 2017-09-010AC).

Patients {#section7-1753466620926956}
========

All patients admitted to the ICU with ARF requiring MV during the study period were enrolled if they had a past history of ILD or a new diagnosis of ILD during the ICU stay. We excluded patients with age less than 20 years, pregnancy, repeated ICU admission at the same hospitalization, or MV use for more than 48 h before ICU admission.

ILD classification {#section8-1753466620926956}
==================

One pulmonologist (WCC) carefully reviewed all medical records and clinical data and images for each study subject whenever available. Hypersensitivity pneumonitis was diagnosed according to the diagnostic criteria by American Thoracic Society (ATS).^[@bibr7-1753466620926956]^ A diagnosis of connective tissue disease (CTD)--related ILD was made when the patient had an established autoimmune disease known to cause ILD based on published criteria.^[@bibr8-1753466620926956][@bibr9-1753466620926956][@bibr10-1753466620926956][@bibr11-1753466620926956]--[@bibr12-1753466620926956]^ Unclassified ILD was diagnosed when there was not enough information to make a specific diagnosis of ILD, according to ATS/European Respiratory Society (ERS) guidelines.^[@bibr1-1753466620926956]^

Data collection and measurement {#section9-1753466620926956}
===============================

Data were extracted from the medical record database. These variables included age, sex, body mass index, smoking status, and comorbidities. We also recorded critical-illness data, such as the cause of respiratory failure, laboratory values, and arterial blood gas at the onset of ARF. Acute exacerbation (AE) of ILD was defined as rapid worsening of respiratory symptoms with increased dyspnea by new radiologic abnormalities within 1 month without evidence of other causes, such as myocardial infarction, pulmonary embolism, or fluid overload.^[@bibr13-1753466620926956]^ Clinical management, including the type of mechanical ventilation, vasopressor use, sedative use, corticosteroid pulse therapy and steroid dosage, oxygenation, and fluid balance, was recorded. The primary outcomes were in-hospital mortality and its risk factors. Secondary outcomes included ICU stay and hospital stay.

Statistical analysis {#section10-1753466620926956}
====================

The results are presented as mean ± standard deviation, median with interquartile range, or number with percentage, as appropriate. We used the Kolmogorov--Smirnov and Shapiro--Wilk tests to examine the normality of continuous variables. The independent *t* test was used to compare normally distributed continuous variables, and the Mann--Whitney *U* test was used to compare nonnormally distributed continuous variables. We used the Pearson χ^[@bibr2-1753466620926956]^ test or Fisher's exact test to compare categorical variables. Variables showing significant differences between survivors and nonsurvivors were entered into univariate and multivariate logistic regression analyses using the enter method to determine factors independently associated with mortality. Odds ratio (OR) and 95% confidence interval (CI) were also calculated. A *p* value \< 0.05 was considered to be statistically significant. All statistical analyses were performed using IBM SPSS Statistics for Windows/Macintosh, Version 22.0 (IBM Corp., Armonk, NY, USA).

Results {#section11-1753466620926956}
=======

During the study period, 1368 patients were admitted to the ICU with ARF requiring MV. Of them, 1286 patients without a diagnosis of ILD were excluded. The remaining 82 patients were included in our study. Among them, 38 patients (46%) received invasive MV and 44 patients (54%) received noninvasive MV for ARF. Overall, the in-hospital mortality was 65.9%. The 90-day and 1-year mortality rates were 69.5% and 76.8%, respectively ([Figure 1](#fig1-1753466620926956){ref-type="fig"}). There was no mortality difference between the invasive and noninvasive MV groups ([Supplemental Figure S1](https://journals.sagepub.com/doi/suppl/10.1177/1753466620926956)).

![Flow chart of the study.\
ARF, acute respiratory failure; ICU, intensive care unit; ILD, interstitial lung disease; MV, mechanical ventilation.](10.1177_1753466620926956-fig1){#fig1-1753466620926956}

Baseline characteristics are summarized in [Table 1](#table1-1753466620926956){ref-type="table"}. In all, 5 patients (6.1%) were diagnosed with hypersensitivity pneumonitis, 30 patients (36.6%) with CTD-related ILDs, 18 patients (22.0%) with idiopathic pulmonary fibrosis, and 29 patients (35.4%) with unclassified ILD. Most patients (89.0%) had at least one pre-existing comorbidity other than ILD. Survivors had significantly better oxygenation at the onset of ARF, less need for vasopressors and sedatives, and better oxygenation during the critically ill period, as shown in [Table 2](#table2-1753466620926956){ref-type="table"}. In addition, survivors stayed longer in the hospital, but not in the ICU, compared with nonsurvivors.

###### 

Baseline characteristics of the 82 subjects with ILD developing ARF.

![](10.1177_1753466620926956-table1)

  ---------------------------------------------------------------------------
  Variable                          Survivors\    Nonsurvivors\   *p* value
                                    (*n* = 28)    (*n* = 54)      
  --------------------------------- ------------- --------------- -----------
  Age (years)                       80.8 ± 13.0   78.9 ± 11.1     0.493

  Male                              23 (82.1%)    44 (81.5%)      0.941

  BMI (kg/m^2^)                     22.0 ± 5.2    22.3 ± 3.7      0.836

  Ever-smoker                       5 (17.9%)     12 (22.2%)      0.644

  Comorbidities                                                   

  Hypertension                      15 (53.6%)    34 (63.0%)      0.411

  Congestive heart failure          6 (21.4%)     21 (38.9%)      0.111

  COPD                              5 (17.9%)     7 (13.0%)       0.533

  Type 2 diabetes mellitus          6 (21.4%)     14 (26.4%)      0.621

  Chronic liver disease             2 (7.1%)      3 (5.7%)        1.0

  Chronic kidney disease            2 (7.1%)      4 (7.4%)        1.0

  Lung cancer                       2 (7.1%)      6 (11.1%)       0.709

  Other neoplastic disease          6 (21.4%)     12(22.2%)       0.934

  Degenerative neurologic disease   3 (11.1%)     6 (11.1%)       1.0

  Classification of ILD                                           0.61

   Hypersensitivity pneumonitis     3 (10.7%)     2 (3.7%)        

   CTD-related ILD                  10 (35.7%)    20 (37.0%)      

   Idiopathic pulmonary fibrosis    5 (17.9%)     13 (24.1%)      

   Unclassified                     10 (35.7%)    19 (35.2%)      
  ---------------------------------------------------------------------------

ARF, acute respiratory failure; BMI, body mass index; COPD, chronic obstructive pulmonary disease; CTD, connective tissue disease; ILD, interstitial lung disease.

###### 

Clinical features during hospitalization of the 82 subjects with ILD developing ARF.

![](10.1177_1753466620926956-table2)

  -------------------------------------------------------------------------------------
  Variable                          Survivors\          Nonsurvivors\       *p* value
                                    (*n* = 28)          (*n* = 54)          
  --------------------------------- ------------------- ------------------- -----------
  At the onset of ARF                                                       

  Cause of respiratory failure                                              0.527

   ILD with AE                      3 (10.7%)           10 (18.5%)          

   Other cause                      25 (89.3%)          44 (81.5%)          

  WBC (cells/mm^3^)                 11,805.4 ± 4529.4   13,065.4 ± 5096.6   0.274

  Hemoglobin (g/dl)                 11.9 ± 2.3          11.4 ± 2.1          0.298

  Albumin (g/dl)                    3.0 ± 0.8           2.7 ± 0.6           0.168

  BUN (mg/dl)                       27.5 ± 19.9         29.4 ± 25.5         0.744

  Creatinine (mg/dl)                1.2 ± 0.7           1.5 ± 1.0           0.156

  Total bilirubin(mg/dl)            0.8 ± 0.4           0.6 ± 0.6           0.29

  ALT (U/l)                         57.6 ± 136.5        46.7 ± 99.6         0.681

  AST (U/l)                         77.8 ± 214.4        92.1 ± 324.8        0.871

  Glucose (mg/dl)                   156.1 ± 43.9        167.8 ± 57.5        0.377

  LDH (U/l)                         379.4 ± 269.6       390.7 ± 179.4       0.871

  CRP (mg/dl)                       9.1 ± 8.2           10.4 ± 9.2          0.52

  Lactate (mg/dl)                   23.3 ± 34.6         27.2 ± 25.1         0.794

  NT-pro-BNP (pg/ml)                1946.3 ± 2241.7     2797.0 ± 2973.9     0.178

  APACHE II                         14.0 ± 5.8          15.9 ± 6.4          0.173

  Arterial blood gas                                                        

   pH                               7.4 ± 0.1           7.4 ± 0.1           0.835

   PaCO~2~ (mmHg)                   46.2 ± 19.7         39.8 ± 9.8          0.056

   HCO~3~^--^(mEq/l)                26.1 ± 7.4          24.0 ± 5.5          0.17

   PaO~2~/FiO~2~                    208.4 ± 125.9       146.1 ± 95.7        0.019

  Management and follow up                                                  

  Type of MV                                                                0.356

   Noninvasive                      17 (60.7%)          27 (50.0%)          

   Invasive                         11 (39.3)           27 (50.0%)          

  Vasopressor                       5 (17.9%)           37 (68.5%)          \< 0.001

  Sedation                          11 (39.3%)          36 (66.7%)          0.017

  Corticosteroid pulse therapy      26 (92.9%)          50 (92.6%)          1.0

  PaO~2~/FiO~2~ Day 3               227.1 ± 73.1        180.4 ± 98.1        0.042

  PaO~2~/FiO~2~ Day 5               256.3 ± 98.4        190.2 ± 96.8        0.018

  PaO~2~/FiO~2~ Day 7               289.5 ± 90.6        188.4 ± 97.0        0.003

  Mean steroid dosage (mg/kg/day)   1.0 ± 0.7           1.2 ± 0.7           0.103

  Cumulative IO                     1709.1 ± 3130.9     2578.2 ± 3349.5     0.258

  Outcome                                                                   

  ICU days                          11.6 ± 8.4          12.4 ± 9.9          0.705

  Hospital days                     39.2 ± 25.6         22.4 ± 23.2         0.004
  -------------------------------------------------------------------------------------

AE, acute exacerbation; ALT, alanine aminotransferase; APACHE II, Acute Physiology and Chronic Health Evaluation II; ARF, acute respiratory failure; AST, aspartate aminotransaminase; BUN, blood urea nitrogen; CRP, C-reactive protein; FiO~2~, fraction of inspired oxygen; HCO3^-^, bicarbonate; ICU, intensive care unit; ILD, interstitial lung disease; IO, intake and output; LDH, lactate dehydrogenase; MV, mechanical ventilation; NT-pro-BNP, N-terminal pro-B-type natriuretic peptide; PaCO~2~, partial pressure of arterial carbon dioxide; PaO~2~, partial pressure of arterial oxygen; WBC, white blood cells.

We also used general and clinical features to compare the invasive and noninvasive MV groups ([Tables 3](#table3-1753466620926956){ref-type="table"} and [4](#table4-1753466620926956){ref-type="table"}). The invasive MV groups had a lower albumin level and higher APACHE II score at the onset of ARF. In addition, the invasive MV group received more vasopressors and more sedation during hospitalization. The invasive MV group spent more days in the ICU than the noninvasive MV group. However, both groups had similar hospital stays, ICU mortality, and in-hospital mortality.

###### 

Baseline characteristics between patients receiving noninvasive and invasive MV.

![](10.1177_1753466620926956-table3)

  --------------------------------------------------------------------------
  Variable                          Noninvasive\   Invasive\     *p* value
                                    (*n* = 44)     (*n* = 38)    
  --------------------------------- -------------- ------------- -----------
  Age (years)                       78.7 ± 12.0    80.5 ± 11.6   0.505

  Male                              35 (79.5%)     32 (84.2%)    0.586

  BMI (kg/m^2^)                     22.8 ± 4.5     21.5 ± 3.8    0.187

  Ever smoker                       12 (27.3%)     5 (13.2%)     0.116

  Comorbidities                                                  

  Hypertension                      24 (54.5%)     25 (65.8%)    0.301

  Congestive heart failure          15 (34.1%)     12 (31.6%)    0.809

  COPD                              9 (20.5%)      3 (7.9%)      0.109

  Type 2 diabetes mellitus          11 (25%)       9 (24.3%)     0.944

  Chronic liver disease             1 (2.3%)       4 (10.5%)     0.181

  Chronic kidney disease            2 (4.5%)       4 (10.5%)     0.408

  Lung cancer                       6 (13.6%)      2 (5.3%)      0.275

  Other neoplastic disease          11 (25%)       7 (18.4%)     0.473

  Degenerative neurologic disease   3 (6.8%)       6 (16.2%)     0.288

  Classification of ILD                                          0.3

   Hypersensitivity pneumonitis     4 (9.1%)       1 (2.6%)      

   CTD-related ILD                  17 (38.6%)     13 (34.2%)    

   Idiopathic pulmonary fibrosis    11 (25%)       7 (18.4%)     

   Unclassified                     12 (27.3%)     17 (44.7%)    
  --------------------------------------------------------------------------

ARF, acute respiratory failure; BMI, body mass index; COPD, chronic obstructive pulmonary disease; CTD, connective tissue disease; ILD, interstitial lung disease; MV, mechanical ventilation.

###### 

Clinical features during hospitalization between patients receiving noninvasive and invasive MV.

![](10.1177_1753466620926956-table4)

  -----------------------------------------------------------------------------------
  Variable                          Noninvasive\       Invasive\          *p* value
                                    (*n* = 44)         (*n* = 38)         
  --------------------------------- ------------------ ------------------ -----------
  At the onset of ARF                                                     

  Cause of respiratory failure                                            0.071

   ILD with AE                      4 (9.1%)           9 (23.7%)          

   Other cause                      40 (90.9%)         29 (76.3%)         

  WBC (cells/mm^3^)                 12282.5 ± 5165.9   13043.4 ± 4651.5   0.488

  Hemoglobin (g/dl)                 11.7 ± 1.9         11.4 ± 2.5         0.484

  Albumin (g/dl)                    3.1 ± 0.6          2.7 ± 0.4          0.003

  BUN (mg/dl)                       26.4 ± 18.9        31.2 ± 27.7        0.373

  Creatinine (mg/dl)                1.3 ± 1.0          1.5 ± 0.9          0.254

  Total bilirubin(mg/dl)            0.8 ± 0.5          0.7 ± 0.4          0.368

  ALT (U/l)                         38.5 ± 65.9        64.3 ± 149.8       0.304

  AST (U/l)                         31.6 ± 29.4        134.8 ± 392.9      0.177

  Glucose (mg/dl)                   153.3 ± 46.3       173.2 ± 57.3       0.118

  LDH (U/l)                         379.4 ± 231.6      396.2 ± 175.7      0.783

  CRP (mg/dl)                       8.3 ± 7.1          11.8 ± 10.3        0.083

  Lactate (mg/dl)                   21.5 ± 17.6        31.4 ± 36.2        0.139

  NT-pro-BNP (pg/ml)                2272.0 ± 2738.0    2805.4 ± 2795.0    0.42

  APACHE II                         12.3 ± 4.4         18.7 ± 6.3         \< 0.001

  Arterial blood gas                                                      

   pH                               7.4 ± 0.1          7.4 ± 0.1          0.797

   PaCO~2~(mmHg)                    43.2 ± 10.4        40.9 ± 17.7        0.486

   HCO~3~^--^(mEq/l)                27.7 ± 6.5         25.5 ± 7.4         0.154

   PaO~2~/FiO~2~                    173.5 ± 92.7       159.0 ± 127.0      0.569

  Management and follow-up                                                

  Vasopressor                       15 (34.1%)         26 (68.4%)         0.002

  Sedation                          13 (29.5%)         34 (89.5%)         \< 0.001

  Corticosteroid pulse therapy      4 (9.3%)           14 (37.8%)         0.002

  PaO~2~/FiO~2~ Day 3               195.3 ± 95.6       199.3 ± 90.0       0.857

  PaO~2~/FiO~2~ Day 5               213.3 ± 118.3      214.3 ± 82.3       0.973

  PaO~2~/FiO~2~ Day 7               229.9 ± 107.9      209.6 ± 104.1      0.539

  Mean steroid dosage (mg/kg/day)   1.2 ± 0.7          1.1 ± 0.7          0.913

  Cumulative IO                     1930.1 ±2 987.3    2688.2 ± 3593.4    0.3

  Outcome                                                                 

  ICU days                          9.9 ± 9.2          14.6 ± 9.2         0.023

  Hospital days                     26.8 ± 22.1        30.2 ± 28.2        0.55

  ICU mortality                     18 (40.9%)         17 (44.7%)         0.727

  In-hospital mortality             27 (61.4%)         27 (71.1%)         0.356
  -----------------------------------------------------------------------------------

AE, acute exacerbation; ALT, alanine aminotransferase; APACHE II, Acute Physiology and Chronic Health Evaluation II; ARF, acute respiratory failure; AST, aspartate aminotransaminase; BUN, blood urea nitrogen; CRP, C-reactive protein; FiO~2~, fraction of inspired oxygen; HCO3^-^, bicarbonate; ICU, intensive care unit; ILD, interstitial lung disease; IO, intake and output; LDH, lactate dehydrogenase; MV, mechanical ventilation; NT-pro-BNP, N-terminal pro-B-type natriuretic peptide; PaCO~2~, partial pressure of arterial carbon dioxide; PaO~2~, partial pressure of arterial oxygen; WBC, white blood cells.

To further elucidate clinical predictors of in-hospital mortality among ILD patients with ARF requiring MV, we used univariate and multivariate logistic regression analyses ([Table 5](#table5-1753466620926956){ref-type="table"}). Significant variables included vasopressor use, sedation use, PF ratio (PaO~2~/FiO~2~, partial pressure of oxygen *versus* fraction of inspired oxygen) at the onset of ARF, and PF ratio at days 3, 5, and 7. After multivariate logistic regression analysis, better PF ratio at day 5 \[OR 0.971, CI (0.946--0.996), *p* = 0.024\] and better PF ratio at day 7 \[OR 0.986, CI (0.974--0.999), *p* = 0.033\] remained independent good prognostic factors. Survivors also had persistently better oxygenation status in the first week of ARF compared with nonsurvivors ([Figure 2](#fig2-1753466620926956){ref-type="fig"}).

###### 

Multivariate logistic regression analysis for risks of in-hospital mortality.

![](10.1177_1753466620926956-table5)

  Variables                      Univariate   Multivariate                                      
  ------------------------------ ------------ -------------- ---------- ------- --------------- -------
  Vasopressor user               9.2          3--28.21       \< 0.001   1.665   0.237--11.724   0.609
  Sedation user                  3.091        1.2--7.962     0.019      1.187   0.154--9.172    0.869
  PF ratio at the onset of ARF   0.995        0.99--0.999    0.027      0.998   0.989--1.007    0.696
  PF ratio Day 3                 0.994        0.989--1.0     0.049      1.029   0.999--1.059    0.058
  PF ratio Day 5                 0.993        0.987--0.999   0.025      0.971   0.946--0.996    0.024
  PF ratio Day 7                 0.99         0.982--0.997   0.009      0.986   0.974--0.999    0.033

ARF, acute respiratory failure; CI, confidence interval; OR, odds ratio; PF ratio, partial pressure of arterial oxygen (PaO~2~)/fraction of inspired oxygen (FiO~2~).

![Oxygenation among survivors and nonsurvivors.\
Survivors had significantly better oxygenation compared with non-survivors at the onset of acute respiratory failure and through the first 7 days. \**p* \< 0.05. PF ratio, partial pressure of arterial oxygen (PaO~2~)/fraction of inspired oxygen (FiO~2~).](10.1177_1753466620926956-fig2){#fig2-1753466620926956}

Discussion {#section12-1753466620926956}
==========

The aim of this study was to explore the in-hospital mortality of ILD patients with ARF requiring MV and its risk factors. The in-hospital mortality among the study subjects was 65.8%. Worse oxygenation on days 5 and 7 independently predicted in-hospital mortality. Although survivors had longer hospital stay, the duration of ICU stay was similar between survivors and nonsurvivors.

A meta-analysis reported that the in-hospital mortality in mixed ILD studies was 52%, though half of these patients had IPF.^[@bibr14-1753466620926956][@bibr15-1753466620926956][@bibr16-1753466620926956][@bibr17-1753466620926956][@bibr18-1753466620926956][@bibr19-1753466620926956][@bibr20-1753466620926956][@bibr21-1753466620926956][@bibr22-1753466620926956][@bibr23-1753466620926956][@bibr24-1753466620926956][@bibr25-1753466620926956]--[@bibr26-1753466620926956]^ Both the in-hospital and ICU mortality rates seem to have decreased in the past 10 years with advancements in critical care and supportive management.^[@bibr14-1753466620926956]^ The in-hospital mortality was higher in our study for two reasons. First, we enrolled only ILD patients with ARF requiring MV. Second, our patients were older and had more comorbidities.

The risk factors for mortality in ILD patients with ARF have been reported by several studies. More severe patients according to APACHE II score,^[@bibr15-1753466620926956],[@bibr17-1753466620926956],[@bibr21-1753466620926956]^ use of MV,^[@bibr15-1753466620926956],[@bibr20-1753466620926956],[@bibr21-1753466620926956],[@bibr24-1753466620926956]^ and hypoxemia^[@bibr17-1753466620926956],[@bibr25-1753466620926956]^ were identified as poor prognostic factors. Fernandez-Perez and coworkers reported that each 10-unit increase in the PF ratio was protective against both in-hospital and 1-year mortality in ILD patients with ARF requiring invasive MV.^[@bibr17-1753466620926956]^ In another study focusing on rapidly progressive interstitial pneumonia patients receiving noninvasive MV, survivors had a significantly higher PF ratio at the start of noninvasive MV but not on admission compared with nonsurvivors. In our study, we also found that worse oxygenation, especially on day 3 and day 5 after the onset of ARF, was a poor prognostic sign for in-hospital mortality. Although poor oxygenation at the onset of ARF had an impact on survival on univariate analysis, its effect diminished after adjustment for other variables.

Before this, there were no direct comparisons of the characteristics between invasive and noninvasive MV users among ILD patients with ARF. Our study is the first to report these findings. At the onset of ARF, invasive MV users had significantly lower albumin levels and higher APACHE II scores. This reflects the need for invasive MV in more severe patients. Additionally, invasive MV users received more vasopressors, more sedatives, and more steroid pulse therapy, possibly for the management of side effects of MV and underlying diseases. The ICU and in-hospital mortality rates between invasive and noninvasive MV users were similar, and were in accordance with previous findings.^[@bibr26-1753466620926956]^ Some studies found that invasive MV users might have higher mortality than noninvasive MV users.^[@bibr20-1753466620926956],[@bibr21-1753466620926956]^ The ventilator setting might be the true culprit. Positive end-expiratory pressure (PEEP) greater than 10 cmH~2~O in the first 24 h of invasive MV has been associated with hospital mortality (OR 17.26) and even 12-month mortality (hazard ratio 4.72) compared with physiological PEEP.^[@bibr17-1753466620926956]^

There are important limitations that should be addressed in this study. First, the study cohort was collected retrospectively in a single center, and the diagnosis of ILD was based mainly on clinical features. Definite pathological diagnosis of ILD was lacking. Second, the case number was relatively small, and some patients were lost to follow up. Third, some patients had "Do-Not-Resuscitate" orders in our study. However, most of our patients signed non-resuscitation notices after initial stabilization of the acute stage, and the medical decision to choose the initial type of mechanical ventilation was not influenced by the request.

In conclusion, in patients with ILD developing ARF requiring MV, the in-hospital mortality rate was high and long-term outcome was poor. Of note, poor PF ratio on day 3 and day 5 after the onset of ARF are risk factors for in-hospital mortality.
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